Crossmark

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2022.100150

Published Print: 2023-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pereira, Rosa M.R.

Dagostin, Marilia A. http://orcid.org/0000-0002-3203-768X
Caparbo, Valeria F.

Sales, Lucas P. http://orcid.org/0000-0003-2439-2240
Pasoto, Sandra G.

Silva, Clovis A.

Yuki, Emily F.N. http://orcid.org/0000-0001-8801-405X
Saad, Carla G.S.

Medeiros-Ribeiro, Ana C.

Kupa, Leonard V.K.

Fusco, Solange R.G.

Martins, Victor A.O. http://orcid.org/0000-0002-5926-3388
Martins, Carolina C.M.F.

Barbas, Carmen Valente

Shinjo, Samuel K.

Aikawa, Nadia E.

Bonfa, Eloisa
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2022-11-23
More Information

This article is maintained by: Elsevier

Article Title: Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2022.100150

Content Type: article

Copyright: © 2022 HCFMUSP. Published by Elsevier España, S.L.U.